Perspective Therapeutics (CATX) vs Establishment Labs (ESTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Establishment Labs (ESTA) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 53.7% versus a loss of 31.1%. Over five years, ESTA leads with a -19.9% price change compared with -57.1% for CATX. Establishment Labs is the larger company by market cap ($1.84 billion vs $303.6 million), about 6.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | ESTA |
|---|---|---|
| Share price | $2.66 | $61.67 |
| Market cap | $303.64M | $1.84B |
| 1-day change | -1.85% | +1.75% |
| YTD return | -3.27% | -15.38% |
| 1-year return | -31.09% | +53.71% |
| 5-year return | -57.10% | -19.91% |
| EPS (TTM) | $-1.33 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $211.08M |
| Revenue growth (YoY) | — | +27.14% |
| Net income (latest FY) | — | $-51.06M |
| Gross margin | — | 69.32% |
| Operating margin | — | -18.48% |
| Net margin | — | -24.19% |
| 52-week high | $6.16 | $97.59 |
| 52-week low | $1.96 | $38.38 |
| Distance from 52-week high | -56.82% | -36.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +362.03% | +66.11% |
| Average volume | 1.65M | 427.13K |
| Shares outstanding | 114.15M | 29.80M |
| Employees | 163 | 1,004 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Establishment Labs is about 6.1 times larger than Perspective Therapeutics by market value ($1.84B vs $303.64M).
- ESTA has outperformed CATX by 84.8 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Health Care · Industrial Specialties · 1,004 employees
CATX vs ESTA FAQ
Which is bigger, Perspective Therapeutics or Establishment Labs?
Establishment Labs (ESTA) is larger, with a market capitalization of $1.84B compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or ESTA?
ESTA returned +53.71% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Establishment Labs in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Industrial Specialties for Establishment Labs.